Argentina, Brazil Join Talks On Forming Regional Regulatory Agency For Caribbean, Latin America

Number of regulators formally agreeing to work toward creating Latin American regulator is growing.

Bridge
• Source: Shutterstock

Two of South America’s most prominent regulatory agencies, Argentina’s Anmat and Brazil’s Anvisa, have signed on to collaborating on creating a pharmaceutical products regulator for Latin America and the Caribbean, additions which could help drive forward the project initiated by three other regulatory agencies earlier in 2023.

Cofepris in Mexico, Invima in Colombia and Cecmed in Cuba signed the Acapulco Declaration in April to formalize talks on creating a regional medicines regulator for countries in Latin America and the Caribbean. Bolivia, the Dominican Republic, Dominica, Ecuador, El Salvador, Honduras and Jamaica also expressed interest in the project

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

Pharma Still Nervous While Riding Trump’s Tariff Rollercoaster

 

The rollout of Trump’s plan has been a policy whiplash, but despite a 90-day pause on tariffs, the US president still appears to be holding a grudge with industry over drug pricing.

Over The Counter: What To Expect From The 61st AESGP Annual Meeting, With Jurate Švarcaite

 
• By 

HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.

Bayer Consumer Health Expands North America And LATAM Supply Capacity

Bayer is investing $52m in its Lerma, Mexico manufacturing site, which the firm said will enable it to increase production of key OTC brands like Aspirin and Alka-Seltzer from 100m to 140m units by 2030.

‘We All Have To Start Somewhere’: How Retailers Are Shaping Perrigo’s Climate Ambitions

 
• By 

Perrigo's retail customers are expecting real "net zero" progress from consumer health manufacturers, which is in turn driving the firm's sustainability ambitions and expectations from their own suppliers, Perrigo’s UK ethical compliance lead Isobel Gay tells HBW Insight in this exclusive interview.

More from Business

Venture Life Focuses On CHC As It Offloads CDMO

 
• By 

UK-based Venture Life is divesting its CDMO business and some non-core products to focus its attention on growing its consumer health operation.

Mitigating Tariff Impacts, Kenvue Adjusts Outlook

 

“The situation has evolved considerably” since Kenvue gave its initial full-year outlook in February, “and remains quite fluid,” says president and CEO Thibaut Mongon as firm reports Q1 net sales decreasing 3.9% to $3.7bn

Looming Tariffs Give Boost To Latest PCH Results While Cutting Costs In Response Takes Priority

 

Looming imposition of tariffs by Trump on imports from most every country had an influence on consumers during the January-March period, particularly on online shopping. Increasing product prices on the table, “but our efforts are going to start with cost savings,” says CFO Christine Sacco.